Immuno-Oncology Combo Active in Recurrent EGFR/ALK Positive NSCLC

(MedPage Today) -- Patients with recurrent EGFR/ALK-positive non-small cell lung cancer (NSCLC) obtained durable remissions with the combination of pembrolizumab (Keytruda) and chemotherapy, a small prospective study showed.
The immuno-oncology...